SLC5A2 and chronic kidney disease: Whilst the DAPA-HF, DELIVER, and EMPEROR trials included patients with mild-moderate renal impairment (mean GFR 60–70 mL/min/1.73 m2), the DAPA-CKD and EMPA-KIDNEY trials explored the use of SGLT2 inhibitors in patients with more severe renal impairment.